Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Improving Current Treatments for Schizophrenia
Nadja P. Marić, Milica Jovičić, Marina Mihaljević, et al.
Drug Development Research (2016) Vol. 77, Iss. 7, pp. 357-367
Closed Access | Times Cited: 76

Showing 1-25 of 76 citing articles:

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders
María S. García‐Gutiérrez, Francisco Navarrete, Ani Gasparyan, et al.
Biomolecules (2020) Vol. 10, Iss. 11, pp. 1575-1575
Open Access | Times Cited: 212
A Machine Learning Model for Diagnosis and Differentiation of Schizophrenia, Bipolar Disorder and Borderline Personality Disorder
Shajahan Wahed, Rama Shdefat Shdefat, Mutaz Abdel Wahed
LatIA (2025) Vol. 3, pp. 133-133
Closed Access | Times Cited: 2
Aerobic exercise and cognitive functioning in schizophrenia: An updated systematic review and meta-analysis
Takeshi Shimada, Shoko Ito, Aya Makabe, et al.
Psychiatry Research (2022) Vol. 314, pp. 114656-114656
Closed Access | Times Cited: 48
DNA methylation and antipsychotic treatment mechanisms in schizophrenia: Progress and future directions
Ellen S. Ovenden, Nathaniel W. McGregor, Robin Emsley, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2017) Vol. 81, pp. 38-49
Closed Access | Times Cited: 78
FAM3 gene family: A promising therapeutical target for NAFLD and type 2 diabetes
Xiaoyan Zhang, Weili Yang, Junpei Wang, et al.
Metabolism (2017) Vol. 81, pp. 71-82
Open Access | Times Cited: 67
<p>Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review</p>
Haiyun Xu, Xiaoyin Zhuang
Neuropsychiatric Disease and Treatment (2019) Vol. Volume 15, pp. 2087-2099
Open Access | Times Cited: 62
Exosome Transplantation From Patients With Schizophrenia Causes Schizophrenia-Relevant Behaviors in Mice: An Integrative Multi-omics Data Analysis
Yang Du, Wen-Long Tan, Lei Chen, et al.
Schizophrenia Bulletin (2021) Vol. 47, Iss. 5, pp. 1288-1299
Open Access | Times Cited: 46
Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone
Paula Soria‐Chacartegui, Gonzalo Villapalos‐García, Pablo Zubiaur, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 42
Artificial intelligence and machine-learning approaches in structure and ligand-based discovery of drugs affecting central nervous system
Vertika Gautam, Anand Gaurav, Neeraj Masand, et al.
Molecular Diversity (2022) Vol. 27, Iss. 2, pp. 959-985
Closed Access | Times Cited: 23
Glucagon-Like Peptide 1: An Introduction and Possible Implications for Neuropsychiatry
Wilfredo López-Ojeda, Robin A. Hurley
Journal of Neuropsychiatry (2024) Vol. 36, Iss. 2, pp. A4-86
Closed Access | Times Cited: 6
Causal link between gut microbiome and schizophrenia: a Mendelian randomization study
Qi Zeng, Min Zhang, Renxi Wang
Psychiatric Genetics (2024)
Closed Access | Times Cited: 4
Identification of Immune-Related Biomarkers of Schizophrenia in the Central Nervous System Using Bioinformatic Methods and Machine Learning Algorithms
Jianjun Weng, Xiaoli Zhu, Yu Ouyang, et al.
Molecular Neurobiology (2024)
Closed Access | Times Cited: 4
Exploring Patterns of Disturbed Eating in Psychosis: A Scoping Review
Nicolette Stogios, Emily R. Smith, Roshanak Asgariroozbehani, et al.
Nutrients (2020) Vol. 12, Iss. 12, pp. 3883-3883
Open Access | Times Cited: 30
Contrasting Typical and Atypical Antipsychotic Drugs
Herbert Y. Meltzer, Erick Gadaleta
FOCUS The Journal of Lifelong Learning in Psychiatry (2021) Vol. 19, Iss. 1, pp. 3-13
Open Access | Times Cited: 26
Neuroinflammation and oxidative stress in schizophrenia: are these opportunities for repurposing?
Zarrin Ansari, Sudhir Pawar, Rajmohan Seetharaman
Postgraduate Medicine (2021) Vol. 134, Iss. 2, pp. 187-199
Closed Access | Times Cited: 24
Impact of age of onset on the course of chronic schizophrenia: factors associated with first hospitalization in a large-scale cross-sectional study
Qingling Hao, Yuan Yang, Shutong Yang, et al.
European Archives of Psychiatry and Clinical Neuroscience (2025)
Closed Access
Dopamine receptor D2 (DRD2) TaqIA gene polymorphism and acute risperidone-induced changes in body weight, plasma glucose and lipid profile
H.S.A. Olasore, Joseph O Faleti, Taiwo Opekitan Afe, et al.
Schizophrenia Research (2025) Vol. 277, pp. 171-176
Closed Access
Axis I Psychiatric Disorders and Substance Abuse: A Systematic Review of Neuroimaging Findings
Bernardo Sosa-Moscoso, Alina Rivadeneira-Limongi, Flores Moncayo, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 7, pp. 2156-2156
Open Access
Effect of aerobic exercise versus cognitive remediation versus a combination of both on cognition among patients with schizophrenia: A three-arm, randomized controlled study
Takeshi Shimada, Shoko Ito, Ayumi Yamanushi, et al.
Psychiatry Research (2025), pp. 116454-116454
Closed Access
Discovery and proof-of-concept study of a novel highly selective sigma-1 receptor agonist for antipsychotic drug development
Wanyu Tang, Zhiyuan Ma, Bang Li, et al.
Acta Pharmaceutica Sinica B (2025)
Open Access
Lumateperone for the Treatment of Schizophrenia.
Amber N. Edinoff, Natalie W Wu, Charles deBoisblanc, et al.
PubMed (2020) Vol. 50, Iss. 4, pp. 32-59
Closed Access | Times Cited: 25
Current emerging therapeutic targets and clinical investigational agents for schizophrenia: Challenges and opportunities
Na Ye, Qi Wang, Yue Li, et al.
Medicinal Research Reviews (2024)
Closed Access | Times Cited: 3
Involvement of oxytocin receptor deficiency in psychiatric disorders and behavioral abnormalities
Jinbao Wei, Huanrui Zheng, Guokai Li, et al.
Frontiers in Cellular Neuroscience (2023) Vol. 17
Open Access | Times Cited: 7
Neuroepigenetics of psychiatric disorders: Focus on lncRNA
Ivana Jovčevska, Alja Videtič Paska
Neurochemistry International (2021) Vol. 149, pp. 105140-105140
Open Access | Times Cited: 17
Exploring the potential pharmacological mechanism of aripiprazole against hyperprolactinemia based on network pharmacology and molecular docking
Lei Yang, Qiuyu Zhang, Chao Li, et al.
Schizophrenia (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top